O
Olusola Olusesan Faluyi
Researcher at Clatterbridge Cancer Centre NHS Foundation Trust
Publications - 29
Citations - 1689
Olusola Olusesan Faluyi is an academic researcher from Clatterbridge Cancer Centre NHS Foundation Trust. The author has contributed to research in topics: Gemcitabine & Internal medicine. The author has an hindex of 8, co-authored 23 publications receiving 1200 citations. Previous affiliations of Olusola Olusesan Faluyi include University of Liverpool & University Health Network.
Papers
More filters
Journal ArticleDOI
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos,John P. Neoptolemos,Daniel H. Palmer,Daniel H. Palmer,Paula Ghaneh,Eftychia E. Psarelli,Juan W. Valle,Christopher Halloran,Christopher Halloran,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting Ma,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Thilo Hackert,Richard J. Jackson,Markus W. Büchler +36 more
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Robert P. Jones,Eftychia-Eirini Psarelli,Richard J. Jackson,Paula Ghaneh,Paula Ghaneh,Christopher Halloran,Christopher Halloran,Daniel H. Palmer,Daniel H. Palmer,Fiona Campbell,Juan W. Valle,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Markus M. Lerch,Julia Mayerle,Julia Mayerle,Christine Tjaden,Oliver Strobel,Thilo Hackert,Markus W. Büchler,John P. Neoptolemos +43 more
TL;DR: There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence in patients who had resection and adjuvant chemotherapy for pancreatic cancer.
Journal ArticleDOI
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial
Daniel H. Palmer,Juan W. Valle,Yuk Ting Ma,Yuk Ting Ma,Olusola Olusesan Faluyi,John P. Neoptolemos,Trine Jensen Gjertsen,Berit Iversen,Jon Amund Eriksen,Anne Sophie Møller,Anne Kirsti Aksnes,Robert M. Miller,Svein Dueland +12 more
TL;DR: In this article, the safety and efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma was evaluated using two schedules of vaccination.
Journal ArticleDOI
Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment
Lorin Dodbiba,Jennifer Teichman,Andrew Fleet,Henry Thai,Bin Sun,Bin Sun,Devang Panchal,Devang Panchal,Devalben Patel,Alvina Tse,Zhuo Chen,Olusola Olusesan Faluyi,Daniel J. Renouf,Hala Girgis,Bizhan Bandarchi,Joerg Schwock,Wei Xu,Robert G. Bristow,Robert G. Bristow,Robert G. Bristow,Ming-Sound Tsao,Ming-Sound Tsao,Gail Darling,Laurie Ailles,Laurie Ailles,Hala El-Zimaity,Geoffrey Liu +26 more
TL;DR: Xenografts maintained similar histology and morphological characteristics with only minor variations even after multiple passaging in most instances.
Journal ArticleDOI
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Julien Edeline,Jean-Frédéric Blanc,Boris Campillo-Gimenez,Yuk Ting Ma,J King,Olusola Olusesan Faluyi,J. Mathurin,S. Ghazi,Daniel H. Palmer,Tim Meyer,Tim Meyer +10 more
TL;DR: In European patients treated with sorafenib, the HAP was the most discriminant prognostic score and may facilitate stratification in trials and inform clinical decision making.